Update on overactive bladder: Pharmacologic approaches on the horizon (Q28203863)

Europe PubMed Central

title

Update on overactive bladder: pharmacologic approaches on the horizon (English)

0 references

Update on overactive bladder: Pharmacologic approaches on the horizon (English)

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

11 March 2024

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

11 March 2024

2

Alan J Wein

0 references

author name string

Eric S. Rovner

series ordinal

1

1 reference

Europe PubMed Central

PubMed publication ID

14499063

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499063

full work available at URL

11 March 2024

language of work or name

English

0 references

publication date

October 2003

0 references

http://link.springer.com/content/pdf/10.1007/s11934-003-0013-3.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

http://link.springer.com/article/10.1007/s11934-003-0013-3/fulltext.html

11 March 2024

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

http://link.springer.com/content/pdf/10.1007/s11934-003-0013-3

11 March 2024

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

Oxybutynin and cognitive dysfunction

11 March 2024

published in

Current urology reports

0 references

volume

4

0 references

issue

5

0 references

page(s)

385-90

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11934-003-0013-3

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-003-0013-3

Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-003-0013-3

Potential therapeutic targets for treatment of the overactive bladder.

21 January 2018

1 reference

12 December 2020

Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers

1 reference

12 December 2020

Topical oxybutynin chloride for relaxation of dysfunctional bladders

1 reference

12 December 2020

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

12 December 2020

Current and future pharmacological treatment for overactive bladder

1 reference

12 December 2020

Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia

1 reference

12 December 2020

Beta3-adrenoceptors in human detrusor muscle

1 reference

12 December 2020

Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland

1 reference

12 December 2020

Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results

1 reference

12 December 2020

Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers

1 reference

12 December 2020

Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin

1 reference

12 December 2020

Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence

1 reference

12 December 2020

Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods

1 reference

12 December 2020

Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism

1 reference

12 December 2020

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group

1 reference

12 December 2020

A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence

1 reference

12 December 2020

Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia

1 reference

12 December 2020

Serotonergic modulation of cat bladder function before and after spinal transection

1 reference

12 December 2020

Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review

1 reference

12 December 2020

Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial

1 reference

12 December 2020

Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro

1 reference

12 December 2020

Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.

1 reference

12 December 2020

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

1 reference

12 December 2020

Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial

1 reference

12 December 2020

Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat

1 reference

12 December 2020

Brain stem influences on the parasympathetic supply to the urinary bladder of the cat

1 reference

12 December 2020

Oxybutynin : A New Drug with Analgesic and Anticholinergic Properties

1 reference

12 December 2020

Cochrane Database of Systematic Reviews

5

3

CD003781

J Hay-Smith

2002

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

Journal of clinical research and drug development

11 March 2024

26

1

439

S Alloussi

1998

1 reference

https://api.crossref.org/works/10.1007/S11934-003-0013-3

11 March 2024

Identifiers